Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway

Archives of Dermatology

Volumn 148, Issue 5, 2012, Pages 628-633

  Huang, Victor ^a   Hepper, Donna ^b   Anadkat, Milan ^a   Cornelius, Lynn ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; DACARBAZINE; DENDRITIC CELL VACCINE; DESONIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; IPILIMUMAB; VEMURAFENIB;

ACNE; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASPIRATION BIOPSY; BLOOD TRANSFUSION; BONE METASTASIS; BRESLOW THICKNESS; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CUTANEOUS MELANOMA; DARIER DISEASE; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISTANT METASTASIS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG ERUPTION; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPERKERATOSIS; INGUINAL LYMPH NODE; LYMPHADENECTOMY; LYMPHADENOPATHY; LYMPHATIC SYSTEM EXAMINATION; MALE; METASTATIC MELANOMA; MOLECULAR DYNAMICS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; ONCOLOGICAL PARAMETERS; PALMOPLANTAR KERATODERMA; PAPULE; PRIORITY JOURNAL; SEBORRHEIC DERMATITIS; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE METASTASIS; SKIN BIOPSY; SKIN CARCINOMA; SKIN DEFECT; SKIN DISEASE; SKIN MANIFESTATION; SKIN METASTASIS; SKIN NODULE; SKIN PRURITUS; SKIN TOXICITY; TUMOR DIFFERENTIATION; VERRUCA VULGARIS; WIDE EXCISION;

AGED; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; FOLLOW-UP STUDIES; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84861393212     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2012.125     Document Type: Article

References (28)

1. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446(7132):153-158. (Pubitemid 46398669)
2. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954. (Pubitemid 34716871)
3. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135-2147. (Pubitemid 41653105)
4. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596-599.
5. Kwon EJ, Kish LS, Jaworsky C. The histologic spectrum of epithelial neoplasms induced by sorafenib. J Am Acad Dermatol. 2009;61(3):522-527.
6. Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol. 2011;23(2):177-182.
7. Donaldson MR, Stetson CL, Smith JL. Invasive squamous cell carcinoma and sorafenib in a black patient. Arch Dermatol. 2011;147(1):133-134.
8. Kim T, Kim J, Lee MG. Inhibition of mutated BRAF in melanoma [letter]. N Engl J Med. 2010;363(23):2261-2262.
9. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
10. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006;98(5):326-334. (Pubitemid 43338212)
11. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099-7109. (Pubitemid 39331023)
12. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, amultikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7(10):3129-3140.
13. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer. 2006;95(5):581-586. (Pubitemid 44325897)
14. Kong HH, Turner ML. Array of cutaneous adverse effects associatedwith sorafenib. J Am Acad Dermatol. 2009;61(2):360-361.
15. Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161(5):1045-1051.
16. Blanchet B, Billemont B, Barete S, et al. Toxicity of sorafenib: clinical and molecular aspects. Expert Opin Drug Saf. 2010;9(2):275-287.
17. Zhang L, Zhou Q, Ma L, Wu Z, Wang Y. Meta-analysis of dermatological toxicities associated with sorafenib. Clin Exp Dermatol. 2011;36(4):344-350.
18. Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008;144(7):886-892. (Pubitemid 352039741)
19. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6(7):491-500. (Pubitemid 40903630)
20. Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res. 2009;15(4):1411-1416.
21. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464(7287):431-435.
22. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427-430.
23. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140(2):209-221.
24. Spencer JM, Kahn SM, Jiang W, DeLeo VA, Weinstein IB. Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas. Arch Dermatol. 1995;131(7):796-800.
25. Pelisson I, Soler C, Pechoux C, et al. c-Myc and c-Ha-ras cellular oncogenes and human papillomaviruses in benign and malignant cutaneous lesions. J Dermatol Sci. 1992;3(1):56-67.
26. Arnault JP, Mateus C, Escudier B, et al. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res. 2012;18(1):263-272.
27. Siegel DH, McKenzie J, Frieden IJ, Rauen KA. Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome. Br J Dermatol. 2011;164(3):521-529.
28. Zenker M. Clinical manifestations of mutations in RAS and related intracellular signal transduction factors. Curr Opin Pediatr. 2011;23(4):443-451.